Aminoglycosides: Difference between revisions
(→Background: fix my spelling) |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 8: | Line 8: | ||
*Nephro and oto toxic. Risk of neuromuscular blockade. | *Nephro and oto toxic. Risk of neuromuscular blockade. | ||
*Can precipitate crisis in patients with [[myasthenia gravis]] | *Can precipitate crisis in patients with [[myasthenia gravis]] | ||
*Include [[gentamicin]] and [[tobramycin]] | |||
==See Also== | ==See Also== | ||
| Line 14: | Line 15: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
{{Template:Clinically Utilized Antibiotics}} | {{Template:Clinically Utilized Antibiotics}} | ||
Revision as of 00:44, 10 July 2017
Background
- Used (alone or with beta-lactam) to treat serious infections due to gram-negative bacilli, e.g.:
- Ill patient with pyelonephritis
- Meningitis (due to pseudomonas, acinetobacter)
- Peritoneal dialysis-associated peritonitis
- Bacterial endocarditis
- Used +/- beta-lactam
- Nephro and oto toxic. Risk of neuromuscular blockade.
- Can precipitate crisis in patients with myasthenia gravis
- Include gentamicin and tobramycin
See Also
References
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||